Cargando…
Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade
DCP-001 is a cell-based cancer vaccine generated by differentiation and maturation of cells from the human DCOne myeloid leukemic cell line. This results in a vaccine comprising a broad array of endogenous tumor antigens combined with a mature dendritic cell (mDC) costimulatory profile, functioning...
Autores principales: | Zuo, Haoxiao, van Lierop, Marie-José C., Kaspers, Jorn, Bos, Remco, Reurs, Anneke, Sarkar, Saheli, Konry, Tania, Kamermans, Alwin, Kooij, Gijs, de Vries, Helga E., de Gruijl, Tanja D., Karlsson-Parra, Alex, Manting, Erik H., Kruisbeek, Ada M., Singh, Satwinder Kaur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625408/ https://www.ncbi.nlm.nih.gov/pubmed/34831455 http://dx.doi.org/10.3390/cells10113233 |
Ejemplares similares
-
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
por: Janssen, Luca L.G., et al.
Publicado: (2023) -
Structural basis of mRNA cap recognition by Dcp1–Dcp2
por: Mugridge, Jeffrey S, et al.
Publicado: (2016) -
The activation of the decapping enzyme DCP2 by DCP1 occurs on the EDC4 scaffold and involves a conserved loop in DCP1
por: Chang, Chung-Te, et al.
Publicado: (2014) -
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
por: de Gruijl, Tanja, et al.
Publicado: (2013) -
Dcp2: an mRNA decapping enzyme that adopts many different shapes and forms
por: Wurm, Jan Philip, et al.
Publicado: (2019)